Authors: D.A. Schorzman
Affilation: Liquidia Technologies, Inc., United States
Pages: 191 - 194
Keywords: PRINT, nanoparticle, fabrication, pharmaceutical
Nanotechnology research is still in its infancy, and while nanotechnology is widely seen as having huge potential, the pharmaceutical industry remains skeptical that success at the bench scale can successfully be translated into high volume products. Recently, a novel new nanofabrication approach, called Particle Replication in Non-wetting Templates (PRINT®), that uniquely enables the precise control over particle size, particle shape, particle composition, particle cargo, particle modulus and particle surface properties, has been developed. The application of 80x320 nm PRINT processed particles as an adjuvant for influenza vaccines has demonstrated a significant improvement in immunogenicity in mice, however, the inherent difficulty in cost-effective scaling of nanofabrication processes to enable GMP production of gram to kilogram quantities of such nanoparticle formulations for clinical trials and eventually affordable, effective pharmaceutical products remains a significant hurdle. Liquidia Technologies, Inc. has been addressing nanoparticle manufacturing scale-up by combining the PRINT particle fabrication process with existing high-volume production methodologies of roll-to-roll processing and the high precision fabrication methods of the microelectronics industry. An overview of the technical challenges, advancements, and ongoing research and development in the area of PRINT processing scale-up, as well as selected pharmaceutical application based results, will be presented.
Nanotech Conference Proceedings are now published in the TechConnect Briefs